Figure 5. STING activation by GB1275 in mouse models and tumor biopsies.

(A) Representative mpIHC staining for pSTAT1, STING, F4/80, CD11b, and CK19 in tumors from 14-day vehicle and GB1275 treated KPC mice. Scale bar, 100μm. Right, percentages of STING⁺ CD11b⁺ cells, STING⁺ TAMs, pSTAT1⁺ TAMs, and pSTAT1⁻ p65⁺ TAMs (n = 7–9 mice per group).

(B) Representative mpIHC staining for STING, CD163, CK19, and CD8α in human PDAC TMAs. Scale bar, 50μm.

(C) Average percentage of STING⁺ TAMs from the TMAs.

(D) Scatter plot showing Spearman’s correlation between the percentage of STING⁺ macrophages and CD8⁺ T cells from B.

(E) Kaplan–Meier survival curves for patients with high STING⁺ TAM infiltration and low STING⁺ TAM infiltration from B.

(F) Representative mpIHC staining for STING, pSTAT1, p65, CD163, and pan-keratin (PanK) in 11 paired tumor biopsies from patients. Scale bar, 50μm.

(G) Relative fold changes of STING⁺, STING^hi macrophages, pSTAT1⁺, pSTAT1^hi macrophages, and nuclear p65⁺ macrophages in paired pre- and post-groups.

(H) Scatter plots showing Spearman’s correlations between the percentage of STING^hi macrophages and pSTAT1^hi macrophages in all 22 tumor biopsies. Scatter plots showing Spearman’s correlation between the percentages of STING^hi macrophages (out of total cells) and CD8⁺ T cells in all 22 tumor biopsies (right). Graphs show the mean ± SEM; *denotes p < 0.05 using the two-sided t-test between two groups, one sample t-tests, and Wilcoxon tests, or the log-rank test for Kaplan–Meier survival curves.

Also see Figure S5, Table S5.